Alivus Life Sciences Share Price
1481.30+33.70 (+2.33%)
+63.78% past 1 Year
Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.
Price Analysis
About
Stock Analysis (SWOT)
QVT
Peer Stocks
1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
LAURUSLABSNSE
ZYDUSLIFENSE
DRREDDYNSE
CIPLANSE
MANKINDNSE
AUROPHARMANSE
LUPINNSE
ALIVUSNSE
Alivus Life Sciences Share Price
1481.30+33.70 (+2.33%)
+63.78% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| - | 6% | 6% | 7% |
| - | 10% | 7% | 16% |
| - | 19% | 34% | 61% |
| 83% | 22% | 19% | 18% |
Peer Comparison
Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
LAURUSLABS
ZYDUSLIFE
DRREDDY
CIPLA
MANKIND
AUROPHARMA
LUPIN
ALIVUS
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 1,769.9 | ₹424202 Cr | 38.68 | 8.29 | 58.23 | ₹11479 Cr |
| 10,064 | ₹264141 Cr | 90.3 | 34.04 | 128.41 | ₹2568 Cr |
| 4,650 | ₹174402 Cr | 82.11 | 14.04 | 106.21 | ₹2163 Cr |
| 2,323 | ₹126811 Cr | 94.64 | 8.17 | 33.94 | ₹889 Cr |
| 1,240.6 | ₹123685 Cr | 27.41 | 9.42 | 62.53 | ₹5040 Cr |
| 1,368.3 | ₹111868 Cr | 39.95 | 11.08 | 59.2 | ₹4196 Cr |
| 1,396.9 | ₹111650 Cr | 38.54 | 10.86 | 52.6 | ₹3879 Cr |
| 2,475 | ₹102196 Cr | 45.57 | 17.23 | 76.26 | ₹1913 Cr |
| 1,694.5 | ₹96951 Cr | 26.11 | 17.95 | 96.84 | ₹3505 Cr |
| 2,015.9 | ₹91301 Cr | 16.51 | 30.95 | 154.35 | ₹5333 Cr |
| 1,481.3 | ₹17843 Cr | 26.64 | 16.03 | 61.16 | ₹564 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | Dec 2020 | Sep 2020 | Jun 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ₹682 Cr | ₹640 Cr | ₹689 Cr | ₹673 Cr | ₹588 Cr | ₹602 Cr | ₹650 Cr | ₹642 Cr | ₹507 Cr | ₹589 Cr | ₹537 Cr | ₹573 Cr | ₹595 Cr | ₹578 Cr | ₹621 Cr | ₹541 Cr | ₹509 Cr | ₹490 Cr | ₹514 Cr | ₹522 Cr | ₹562 Cr | ₹525 Cr | ₹467 Cr | ₹500 Cr | ₹521 Cr | ₹397 Cr |
| ₹20 Cr | ₹22 Cr | ₹23 Cr | ₹14 Cr | ₹15 Cr | ₹9 Cr | ₹10 Cr | ₹10 Cr | ₹9 Cr | ₹5 Cr | ₹3 Cr | ₹2 Cr | ₹5 Cr | ₹2 Cr | ₹3 Cr | ₹7 Cr | ₹10 Cr | ₹9 Cr | ₹5 Cr | ₹4 Cr | ₹2 Cr | ₹4 Cr | ₹34 L | ₹37 L | ₹1 L | ₹2 Cr |
| ₹702 Cr | ₹663 Cr | ₹712 Cr | ₹687 Cr | ₹603 Cr | ₹611 Cr | ₹660 Cr | ₹652 Cr | ₹515 Cr | ₹594 Cr | ₹540 Cr | ₹574 Cr | ₹601 Cr | ₹580 Cr | ₹624 Cr | ₹547 Cr | ₹519 Cr | ₹499 Cr | ₹519 Cr | ₹526 Cr | ₹564 Cr | ₹529 Cr | ₹468 Cr | ₹501 Cr | ₹521 Cr | ₹399 Cr |
| ₹439 Cr | ₹449 Cr | ₹495 Cr | ₹461 Cr | ₹427 Cr | ₹447 Cr | ₹467 Cr | ₹467 Cr | ₹388 Cr | ₹444 Cr | ₹410 Cr | ₹413 Cr | ₹441 Cr | ₹398 Cr | ₹426 Cr | ₹406 Cr | ₹376 Cr | ₹353 Cr | ₹381 Cr | ₹386 Cr | ₹404 Cr | ₹373 Cr | ₹306 Cr | ₹354 Cr | ₹402 Cr | ₹267 Cr |
| ₹285 Cr | ₹234 Cr | ₹237 Cr | ₹245 Cr | ₹194 Cr | ₹181 Cr | ₹209 Cr | ₹201 Cr | ₹143 Cr | ₹165 Cr | ₹145 Cr | ₹174 Cr | ₹172 Cr | ₹195 Cr | ₹209 Cr | ₹152 Cr | ₹154 Cr | ₹156 Cr | ₹147 Cr | ₹150 Cr | ₹169 Cr | ₹164 Cr | ₹170 Cr | ₹155 Cr | ₹127 Cr | ₹140 Cr |
| ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹1 Cr | ₹46 L | ₹34 L | ₹35 L | ₹36 L | ₹39 L | ₹40 L | ₹40 L | ₹12 L | ₹16 L | ₹13 L | ₹14 L | ₹13 L | ₹6 L | ₹7 Cr | ₹21 Cr | ₹21 Cr | ₹22 Cr | ₹22 Cr | ₹23 Cr |
| ₹262 Cr | ₹212 Cr | ₹216 Cr | ₹198 Cr | ₹174 Cr | ₹163 Cr | ₹191 Cr | ₹185 Cr | ₹127 Cr | ₹150 Cr | ₹130 Cr | ₹161 Cr | ₹159 Cr | ₹182 Cr | ₹198 Cr | ₹141 Cr | ₹144 Cr | ₹146 Cr | ₹138 Cr | ₹140 Cr | ₹153 Cr | ₹135 Cr | ₹141 Cr | ₹125 Cr | ₹97 Cr | ₹108 Cr |
| ₹197 Cr | ₹160 Cr | ₹163 Cr | ₹150 Cr | ₹130 Cr | ₹122 Cr | ₹142 Cr | ₹137 Cr | ₹95 Cr | ₹111 Cr | ₹98 Cr | ₹119 Cr | ₹119 Cr | ₹135 Cr | ₹146 Cr | ₹105 Cr | ₹107 Cr | ₹109 Cr | ₹99 Cr | ₹104 Cr | ₹115 Cr | ₹101 Cr | ₹105 Cr | ₹93 Cr | ₹72 Cr | ₹81 Cr |
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Share Warrants & Outstandings
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 |
|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | — | — | — | — |
| ₹25 Cr | ₹25 Cr | ₹25 Cr | ₹25 Cr | ₹25 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹1 L |
| ₹7 Cr | ₹10 Cr | ₹11 Cr | ₹7 Cr | ₹3 Cr | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹3300 Cr | ₹2783 Cr | ₹2297 Cr | ₹2107 Cr | ₹2026 Cr | ₹751 Cr | ₹400 Cr | ₹86 Cr | -₹1 Cr |
| ₹3300 Cr | ₹2783 Cr | ₹2297 Cr | ₹2107 Cr | ₹2026 Cr | ₹751 Cr | ₹400 Cr | ₹86 Cr | -₹1 Cr |
| ₹3332 Cr | ₹2817 Cr | ₹2332 Cr | ₹2138 Cr | ₹2054 Cr | ₹753 Cr | ₹402 Cr | ₹88 Cr | -₹1 Cr |
| ₹58 Cr | ₹54 Cr | ₹49 Cr | ₹42 Cr | ₹31 Cr | ₹23 Cr | ₹16 Cr | ₹7 Cr | ₹0 |
| ₹49 Cr | ₹51 Cr | ₹15 Cr | ₹17 Cr | ₹1 Cr | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹36 Cr | ₹361 Cr | ₹693 Cr | ₹8 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹143 Cr | ₹466 Cr | ₹757 Cr | ₹67 Cr | ₹33 Cr | ₹23 Cr | ₹16 Cr | ₹7 Cr | ₹0 |
| — | — | — | — | — | — | — | — | — |
| ₹372 Cr | ₹390 Cr | ₹369 Cr | ₹427 Cr | ₹308 Cr | ₹221 Cr | ₹201 Cr | ₹183 Cr | ₹1 L |
| ₹99 Cr | ₹63 Cr | ₹58 Cr | ₹55 Cr | ₹50 Cr | ₹967 Cr | ₹1084 Cr | ₹1181 Cr | ₹1 Cr |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹2 L | ₹2 L | ₹0 |
| ₹211 Cr | ₹17 Cr | ₹12 Cr | ₹533 Cr | ₹389 Cr | ₹257 Cr | ₹22 Cr | ₹16 Cr | ₹1 L |
| ₹682 Cr | ₹470 Cr | ₹439 Cr | ₹1015 Cr | ₹747 Cr | ₹1445 Cr | ₹1307 Cr | ₹1380 Cr | ₹1 Cr |
| ₹4157 Cr | ₹3754 Cr | ₹3528 Cr | ₹3220 Cr | ₹2834 Cr | ₹2221 Cr | ₹1726 Cr | ₹1475 Cr | ₹9 L |
| ₹5 Cr | ₹5 Cr | ₹5 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹3 Cr | ₹0 |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹2 L | ₹2 L | ₹0 |
| — | — | — | — | — | — | — | — | — |
| ₹1367 Cr | ₹1219 Cr | ₹1012 Cr | ₹936 Cr | ₹706 Cr | ₹652 Cr | ₹595 Cr | ₹476 Cr | ₹10,000 |
| ₹329 Cr | ₹264 Cr | ₹207 Cr | ₹156 Cr | ₹116 Cr | ₹79 Cr | ₹49 Cr | ₹19 Cr | ₹0 |
| ₹1038 Cr | ₹955 Cr | ₹805 Cr | ₹781 Cr | ₹590 Cr | ₹573 Cr | ₹546 Cr | ₹456 Cr | ₹10,000 |
| ₹273 Cr | ₹94 Cr | ₹101 Cr | ₹49 Cr | ₹92 Cr | ₹14 Cr | ₹11 Cr | ₹80 Cr | ₹0 |
| ₹8 L | ₹8 L | ₹8 L | ₹8 L | ₹8 L | ₹8 L | ₹8 L | ₹8 L | ₹0 |
| ₹8 L | ₹8 L | ₹8 L | ₹8 L | ₹8 L | ₹8 L | ₹8 L | ₹8 L | ₹0 |
| ₹12 Cr | ₹361 Cr | ₹701 Cr | ₹9 Cr | ₹20 Cr | ₹11 Cr | ₹8 Cr | ₹8 Cr | ₹0 |
| ₹1334 Cr | ₹1418 Cr | ₹1612 Cr | ₹852 Cr | ₹706 Cr | ₹598 Cr | ₹565 Cr | ₹545 Cr | ₹10,000 |
| — | — | — | — | — | — | — | — | — |
| ₹780 Cr | ₹478 Cr | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| ₹692 Cr | ₹674 Cr | ₹667 Cr | ₹604 Cr | ₹516 Cr | ₹513 Cr | ₹413 Cr | ₹401 Cr | ₹4 L |
| ₹1073 Cr | ₹970 Cr | ₹765 Cr | ₹807 Cr | ₹673 Cr | ₹620 Cr | ₹639 Cr | ₹448 Cr | ₹3 L |
| ₹2 Cr | ₹71 Cr | ₹302 Cr | ₹309 Cr | ₹512 Cr | ₹116 Cr | ₹10 Cr | ₹2 Cr | ₹70,000 |
| ₹39 Cr | ₹42 Cr | ₹92 Cr | ₹72 Cr | ₹6 Cr | ₹26 Cr | ₹21 Cr | ₹6 Cr | ₹0 |
| ₹237 Cr | ₹100 Cr | ₹91 Cr | ₹577 Cr | ₹420 Cr | ₹348 Cr | ₹78 Cr | ₹74 Cr | ₹80,000 |
| ₹2824 Cr | ₹2335 Cr | ₹1916 Cr | ₹2369 Cr | ₹2127 Cr | ₹1623 Cr | ₹1160 Cr | ₹931 Cr | ₹8 L |
| ₹2141 Cr | ₹1865 Cr | ₹1477 Cr | ₹1354 Cr | ₹1381 Cr | ₹178 Cr | -₹147 Cr | -₹450 Cr | -₹1 Cr |
| ₹4157 Cr | ₹3754 Cr | ₹3528 Cr | ₹3220 Cr | ₹2834 Cr | ₹2221 Cr | ₹1726 Cr | ₹1475 Cr | ₹9 L |
| ₹271 | ₹229 | ₹189 | ₹174 | ₹167 | ₹768 | ₹2,049 | ₹450 | -₹1,398 |
| ₹271 | ₹229 | ₹189 | ₹174 | ₹167 | ₹70 | ₹37 | ₹8 | -₹25 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Cash & Cash Equivalent on Amalgamation / Take over / Merger
Closing Cash & Cash Equivalent
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 |
|---|---|---|---|---|---|---|---|---|
| ₹751 Cr | ₹654 Cr | ₹631 Cr | ₹629 Cr | ₹565 Cr | ₹471 Cr | ₹421 Cr | ₹228 Cr | -₹1 L |
| ₹116 Cr | ₹81 Cr | ₹79 Cr | ₹45 Cr | ₹71 Cr | ₹133 Cr | ₹57 Cr | -₹101 Cr | ₹0 |
| -₹129 Cr | -₹180 Cr | -₹134 Cr | -₹214 Cr | ₹100 Cr | -₹108 Cr | -₹190 Cr | -₹93 Cr | -₹47 L |
| ₹739 Cr | ₹554 Cr | ₹576 Cr | ₹460 Cr | ₹736 Cr | ₹497 Cr | ₹288 Cr | ₹34 Cr | -₹48 L |
| ₹565 Cr | ₹392 Cr | ₹414 Cr | ₹306 Cr | ₹598 Cr | ₹388 Cr | ₹195 Cr | ₹10 Cr | -₹48 L |
| -₹570 Cr | -₹616 Cr | -₹116 Cr | -₹147 Cr | -₹122 Cr | -₹69 Cr | -₹51 Cr | -₹9 Cr | ₹0 |
| -₹64 Cr | -₹6 Cr | -₹279 Cr | -₹388 Cr | -₹79 Cr | -₹214 Cr | -₹137 Cr | ₹54 L | ₹49 L |
| -₹69 Cr | -₹230 Cr | ₹18 Cr | -₹228 Cr | ₹397 Cr | ₹106 Cr | ₹8 Cr | ₹2 Cr | ₹50,000 |
| ₹71 Cr | ₹301 Cr | ₹284 Cr | ₹512 Cr | ₹116 Cr | ₹10 Cr | ₹2 Cr | ₹70,000 | ₹20,000 |
| ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹8 L | ₹0 |
| ₹2 Cr | ₹71 Cr | ₹301 Cr | ₹284 Cr | ₹512 Cr | ₹116 Cr | ₹10 Cr | ₹2 Cr | ₹70,000 |
Fundamental Ratios
Consolidated
Standalone
No results found
Alivus Life Sciences Share Price
1481.30+33.70 (+2.33%)
+63.78% past 1 Year
Technical meters
Oscillators
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 5
Bearish signals: 4 out of 9 oscillators
RSI
70.00Buy
STOCH %K
92.02Sell
MACD Level(12,26)
18.92Buy
Ultimate Oscillator
55.36Buy
Aroon Oscillator
12.00Sell
BOP
0.55Buy
CCI
175.75Sell
Williams %R
-7.98Sell
Momentum
136.90Buy
Moving averages
Strong SellSellNeutralBuyStrong Buy
Bullish signals: 9
Bearish signals: 0 out of 9 moving averages
EMA 9
1392.32Buy
SMA 9
1362.91Buy
EMA 21
1363.51Buy
SMA 21
1346.33Buy
EMA 50
1340.97Buy
SMA 50
1365.68Buy
EMA 200
1188.01Buy
SMA 200
1128.87Buy
WMA 20
1356.06Buy
Pivot
Pivot
Classic
Resistance 5
1793.87
Resistance 4
1709.87
Resistance 3
1625.87
Resistance 2
1541.87
Resistance 1
1494.73
Pivot
1457.87
Support 1
1410.73
Support 2
1373.87
Support 3
1289.87
Support 4
1205.87
Support 5
1121.87
High & lows
1 Day
1 Week
1 Month
3 Months
6 Months
Year to Date
1 Year
3 Years
5 Years
10 Years
All Time
Alivus Life Sciences Share Price
1481.30+33.70 (+2.33%)
+63.78% past 1 Year
Shareholding summary
Shareholding Pattern
Quarterly
Yearly
Name
Promoters
FII
DII - Others
DII - MFs
Retail & Others
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|
| 74.85% | 74.87% | 74.87% | 74.91% | 74.91% | 74.94% |
| 5.93% | 5.54% | 5.30% | 5.08% | 6.84% | 6.42% |
| 1.74% | 1.53% | 1.64% | 1.69% | 1.60% | 1.56% |
| 5.29% | 5.65% | 5.63% | 5.44% | 3.87% | 4.06% |
| 12.19% | 12.41% | 12.56% | 12.88% | 12.78% | 13.02% |
Bulk & block deals
Name
Icici Prudential Mutual Fund
Societe Generale
Bnp Paribas Arbitrage
Polar Capital Funds Plc-Healthcare Opportunities Fund
Nk Securities Research Private Limited
Nk Securities Research Private Limited
| Deal Date | Action | Deal Value | Deal Price | Qty Traded | Deal Type | %Stake Traded | Exchange |
|---|---|---|---|---|---|---|---|
| 04 Dec 2025 | Purchase | 84.38 Cr | ₹870 | 9.70 L | Bulk | 0.790595 | BSE |
| 25 Jan 2024 | Purchase | 12.09 Cr | ₹799.55 | 1.51 L | Block | 0.123134 | BSE |
| 25 Jan 2024 | Sell | 12.09 Cr | ₹799.55 | 1.51 L | Block | 0.123134 | BSE |
| 09 Aug 2021 | Purchase | 61.24 Cr | ₹732.55 | 8.36 L | Bulk | 0.68094 | NSE |
| 06 Aug 2021 | Purchase | 72.83 Cr | ₹765.77 | 9.51 L | Bulk | 0.774689 | NSE |
| 06 Aug 2021 | Sell | 72.87 Cr | ₹766.12 | 9.51 L | Bulk | 0.774689 | NSE |
Insider trading & SAST
Client name
Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Ltd
Glenmark Pharmaceuticals Limited
Glenn Mario Saldanha
Glenmark Pharmaceuticals Ltd
Nirma Ltd
Glenmark Pharmaceuticals Ltd
Nirma Ltd
Glenmark Pharmaceuticals Limited
| Reported on | Client category | Action | %Stake traded | Holding % post deal | Deal value | Deal price | Qty traded | Deal period | Deal mode | Post transaction holding | Insider/SAST | Regulation type | Security type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 24 Dec 2024 | Promoter | Pledge | 20 | — | 0 | — | 2.45 Cr | 12 Mar 2024 | Release | 96,09,571 | SAST | Reg31 | — |
| 22 Jul 2024 | Promoter | Disposal | 7.84 | — | 0 | — | 96.10 L | 11 Jul 2024 - 12 Jul 2024 | Offer For Sale | — | SAST | 29(2) | — |
| 17 Jul 2024 | Promoter | Non disposal undertaking | — | — | 0 | — | 96.10 L | 04 Jul 2024 | Release | 0 | SAST | Reg31 | — |
| 15 Jul 2024 | Promoter | Disposal | 7.842806 | 0 | 798.30 Cr | ₹830.73 | 96.10 L | 11 Jul 2024 - 12 Jul 2024 | Others | 0 | Insider Trading | — | Equity Shares |
| 15 Jul 2024 | Promoter Group | Disposal | 0.006366 | 0 | 64.71 L | ₹829.63 | 7.80 K | 11 Jul 2024 - 12 Jul 2024 | Others | 0 | Insider Trading | — | Equity Shares |
| 19 Mar 2024 | Promoter | Disposal | 20 | 7.84 | 0 | — | 2.45 Cr | 12 Mar 2024 | Off Market | 96,09,571 | SAST | 29(2) | — |
| 19 Mar 2024 | Promoter | Acquisition | 20 | 75 | 0 | — | 2.45 Cr | 12 Mar 2024 | Off Market | 9,18,96,285 | SAST | 29(2) | — |
| 14 Mar 2024 | Promoter | Disposal | 55 | 27.84 | 0 | — | 6.74 Cr | 06 Mar 2024 | Off Market | 3,41,15,006 | SAST | 29(2) | — |
| 14 Mar 2024 | Promoter | Acquisition | 55 | 55 | 0 | — | 6.74 Cr | 05 Mar 2024 - 06 Mar 2024 | Off Market | 6,73,90,850 | SAST | 29(1) | — |
| 13 Mar 2024 | Promoter | Disposal | 19.999996 | 7.84 | 1,465.40 Cr | ₹597.99 | 2.45 Cr | 12 Mar 2024 | Off Market | 96,09,571 | Insider Trading | — | Equity Shares |
Alivus Life Sciences Share Price
1481.30+33.70 (+2.33%)
+63.78% past 1 Year
Glenmark Life Sciences Limited is a leading developer and manufacturer of select high value, non-commoditized active pharmaceutical ingredients (APIs) in chronic therapeutic areas, including cardiovascular disease (CVS), central nervous system
Corporate Actions
Date
Type
Details
Company details
Alivus Life Sciences Share Price
1481.30+33.70 (+2.33%)
+63.78% past 1 Year
Corporate filings & documents
Announcements
Annual reports
Concalls & investor presentations
Alivus Life Sciences Share Price
1481.30+33.70 (+2.33%)
+63.78% past 1 Year
News
Alivus Reports Strong Q2 EBITDA Growth And Margin Expansion
Equity
ALIVUS
Alivus Q2 Net Profit Rises 51.5 Percent With Stronger Revenue And Margins
Equity
ALIVUS
Alivus Q2 Revenue Rises 16 Percent Year on Year to Rs 682 Crores
Equity
ALIVUS
Alivus Life Sciences Acquires Stake In Torrent Urja For Renewable Energy Compliance
Equity
ALIVUS
Alivus Life Sciences to acquire 76 percent stake in Iqgen-X Pharma
Equity
ALIVUS
Alivus Life Sciences Q1 EBITDA grows with strong margin expansion YoY
Equity
ALIVUS
Alivus Life Sciences reports strong Q1 revenue growth of 6.7 percent YoY
Equity
ALIVUS
Alivus Life Sciences Q1 net profit rises 33 percent year-on-year
Equity
ALIVUS
Alivus Life Sciences to host Q1 FY27 earnings conference call on July 31
Equity
ALIVUS
Alivus Life Sciences Reports Q4 EBITDA Growth to Rs 210 Crores, Margin Expands to 31.13%
Equity
ALIVUS
Alivus Life Sciences Reports Strong Q4FY25 Earnings with Profit and Revenue Growth
Equity
ALIVUS
Alivus Life Sciences reports Profit after tax of 162.66 Crores, in the March 2026 quarter
Equity
ALIVUS
Alivus Life Sciences informs about disclosure
Equity
ALIVUS
Alivus Life Sciences Fire Incident At Dahej: Production Recovery Timeline Announced
Equity
ALIVUS
Alivus Life Sciences informs about updates
Equity
ALIVUS
Fire at Alivus Life Sciences API Plant in Dahej Injures Three; Company Assessing Damages.
Equity
ALIVUS
Alivus Life Sciences Management Guides for Additional CDMO Projects by Q1 FY27, Double-Digit Growth from FY28-29.
Equity
ALIVUS
Alivus Life Sciences Solapur Plant Operations Timeline and Capacity Utilization Guidance
Equity
ALIVUS
Alivus Life Sciences Revises FY26 Capex Guidance Down to INR450 Crores from INR600 Crores.
Equity
ALIVUS
Alivus Life Sciences Raises EBITDA Margin Guidance to 30%-32% from 28%-30% on Efficiencies, Launches.
Equity
ALIVUS